Related references
Note: Only part of the references are listed.Serial blood-based analysis of AR-V7 in men with advanced prostate cancer
M. Nakazawa et al.
ANNALS OF ONCOLOGY (2015)
Survival with Newly Diagnosed Metastatic Prostate Cancer in the Docetaxel Era'': Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)
Nicholas David James et al.
EUROPEAN UROLOGY (2015)
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study
Michael T. Schweizer et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate Cancer
Maria Thadani-Mulero et al.
CANCER RESEARCH (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The Link Between Androgen Receptor Splice Variants and Castration-Resistant Prostate Cancer
Cynthia C. T. Sprenger et al.
HORMONES & CANCER (2014)
Cancer statistics, 2013
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2013)
Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate
Alison H. M. Reid et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Molecular determinants of resistance to antiandrogen therapy
CD Chen et al.
NATURE MEDICINE (2004)
Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma
DJ Samson et al.
CANCER (2002)
Share Paper
